Bristol Interim CEO Cornelius Becomes Permanent Chief Exec
This article was originally published in The Pink Sheet Daily
Executive Summary
James Cornelius has delayed retirement to stay with the company as permanent CEO through early 2009.
You may also be interested in...
Bristol Restructures To Cut Costs, Transform Into Next-Generation Biopharma
Plan to achieve $1.5 billion in cost reductions by 2010 includes a 10 percent net reduction in head count.
Bristol Restructures To Cut Costs, Transform Into Next-Generation Biopharma
Plan to achieve $1.5 billion in cost reductions by 2010 includes a 10 percent net reduction in head count.
Ready, Set, Cut: Bristol Headcount Reductions Imminent
Drug maker will release details on its productivity initiative during an investor meeting Dec. 5.